|Bid||2.1100 x 2200|
|Ask||2.1800 x 800|
|Day's Range||2.1100 - 2.2400|
|52 Week Range||1.3900 - 19.2850|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.80|
– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year– New portfolio prioritization and capital allocation strategy extends expected cash runway by an additional two years– Cash balance of $223.6 million anticipated to fund key milestones through 2025 REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immu
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Carriage Services, Pool, The Buckle, Bolt Biotherapeutics and Titan Machinery are part of screen of the week article.